Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma

Journal of Glaucoma

Volumn 19, Issue 3, 2010, Pages 212-218

  Fakhraie, Ghasem ^a,b   Jay Katz, L ^b   Prasad, Arun ^b   Eslami, Yadollah ^a   Sabour, Siamak ^c,d   Zarei, Reza ^a   Moghimi, Sasan ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bevacizumab; Neovascular glaucoma; Trabeculectomy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MITOMYCIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; DRUG ANTAGONISM; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOVASCULAR GLAUCOMA; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TRABECULECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MITOMYCIN; PROSPECTIVE STUDIES; TRABECULECTOMY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952047999     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181aae928     Document Type: Article

References (50)

1. Bresnick GH. Assessment of the eye at risk of neovascularization. Eye. 1991; 5: 198-213.
2. Brown GC, Magargal LE, Schachat A, et al. Neovascular glaucoma. Etiologic considerations. Ophthalmology. 1984; 91: 315-320.
3. Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol. 1978; 22: 291-312.
4. Weiss DI. Vascular insufficiency (neovascular) glaucoma. An integrating pathogenetic concept. Trans Ophthalmol Soc UK. 1977; 97: 280-287.
5. Pe’er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998; 105: 412-416.
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-1487.
7. Pe’er J, Folberg R, Itin A, et al. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996; 80: 241-245.
8. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146: 1029-1039.
9. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007; 18: 502-508.
10. Little HL, Rosenthal AR, Dellaporta A, et al. The effect of pan-retinal photo-coagulation on rubeosis iridis. Am J Ophthalmol. 1976; 81: 804-809.
11. Wand M, Dueker DK, Aiello LM, et al. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol. 1978; 86: 332-339.
12. May DR, Bergstrom TJ, Parmet AJ, et al. Treatment of neovascular glaucoma with transscleral panretinal cryotherapy. Ophthalmology. 1980; 87: 1106-1111.
13. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology. 1989; 96: 92-95.
14. Fernández-Vigo J, Castro J, Macarro A. Diabetic iris neovascularization. Natural history and treatment. Acta Ophthalmol Scand. 1997; 75: 89-93.
15. Sivak-Callcott JA, O’Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001; 108: 1767-1776.
16. Mietz H, Raschka B, Krieglstein GK. Risk factors for failures of trabeculectomies performed without antimetabolites. Br J Ophthalmol. 1999; 83: 814-821.
17. Katz LJ, Spaeth GL. Surgical management of the secondary glaucomas: part I. Ophthalmic Surg. 1987; 18: 826-834.
18. Tsai JC, Feuer WJ, Parrish RK II, et al. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology. 1995; 102: 887-892.
19. Sisto D, Vetrugno M, Trabucco T, et al. The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up. Acta Ophthalmol Scand. 2007; 85: 267-271.
20. Eid TE, Katz LJ, Spaeth GL, et al. Tube-shunt surgery versus neodymium: YAG cyclophotocoagulation in the management of neovascular glaucoma. Ophthalmology. 1997; 104: 1692-1700.
21. Goulet RJ III, Phan AD, Cantor LB, et al. Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant. Ophthalmology. 2008; 115: 1141-1147.
22. Every SG, Molteno AC, Bevin TH, et al. Long-term results of Molteno implant insertion in cases of neovascular glaucoma. Arch Ophthalmol. 2006; 124: 355-360.
23. Yalvac IS, Eksioglu U, Satana B, et al. Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye. 2007; 21: 65-70.
24. Sidoti PA, Dunphy TR, Baerveldt G, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology. 1995; 102: 1107-1118.
25. Mastropasqua L, Carpineto P, Ciancaglini M, et al. Long-term results of Krupin-Denver valve implants in filtering surgery for neovascular glaucoma. Ophthalmologica. 1996; 210: 203-206.
26. Pastor SA, Singh K, Lee DA, et al. Cyclophotocoagulation: a report by the American Academy of Ophthalmology. Ophthalmology. 2001; 108: 2130-2138.
27. Pokroy R, Greenwald Y, Pollack A, et al. Visual loss after transscleral diode laser cyclophotocoagulation for primary open-angle and neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2008; 39: 22-29.
28. Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007; 91: 1631-1635.
29. Nabili S, Kirkness CM. Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma. Eye. 2004; 18: 352-356.
30. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998; 105: 232-237.
31. Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006; 26: 871-876.
32. Sone H, Okuda Y, Kawakami Y, et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care. 1996; 19: 1306-1307.
33. Mason JO III, Albert MA Jr, Mays A, et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina. 2006; 26: 839-841.
34. Silva Paula J, Jorge R, Alves Costa R, et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006; 84: 556-557.
35. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina. 2006; 26: 352-354.
36. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Laser Imaging. 2006; 37: 144-146.
37. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006; 26: 354-356.
38. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006; 142: 158-160.
39. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006; 142: 1054-1056.
40. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996; 114: 964-970.
41. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996; 114: 66-71.
42. Cornish KS, Ramamurthi S, Saidkasimova S, et al. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye. 2008 [Epub ahead of print].
43. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114: 855-859.
44. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006; 26: 257-261.
45. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006; 26: 262-269.
46. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008; 25: 438-443.
47. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007; 39: 121-122.
48. Nissen N, Polverini PJ, Koch AE. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998; 152: 1445-1452.
49. Stadelmann W, Digenis A, Tobin G. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg. 1998; 176(suppl 2A): 26S-38S.
50. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91: 173-180.